bluebird bio (bluebird bio) Liabilities-to-Assets : 0.64 (As of Sep. 2023)

View and export this data going back to 2013. Start your Free Trial

What is bluebird bio Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. bluebird bio's Total Liabilities for the quarter that ended in Sep. 2023 was $391.07 Mil. bluebird bio's Total Assets for the quarter that ended in Sep. 2023 was $613.61 Mil. Therefore, bluebird bio's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 was 0.64.

bluebird bio Liabilities-to-Assets Historical Data

The historical data trend for bluebird bio's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

bluebird bio Liabilities-to-Assets Chart

bluebird bio Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Liabilities-to-Assets

Get a 7-Day Free Trial

0.16

0.26

0.24

0.37

0.65

bluebird bio Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Liabilities-to-Assets	Get a 7-Day Free Trial															0.70	0.65	0.49	0.56	0.64

Competitive Comparison of bluebird bio's Liabilities-to-Assets

For the Biotechnology subindustry, bluebird bio's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bluebird bio's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bluebird bio's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where bluebird bio's Liabilities-to-Assets falls into.

bluebird bio Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

bluebird bio's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Liabilities-to-Assets (A: Dec. 2022 )	=	Total Liabilities	/	Total Assets
	=	358.559	/	554.902
	=	0.65

bluebird bio's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2023 is calculated as

Liabilities-to-Assets (Q: Sep. 2023 )	=	Total Liabilities	/	Total Assets
	=	391.072	/	613.608
	=	0.64

bluebird bio (NAS:BLUE) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

bluebird bio Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of bluebird bio's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

bluebird bio (bluebird bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » Liabilities-to-Assets

Comparable Companies

Traded in Other Exchanges

BLUE:Mexico

Address

455 Grand Union Boulevard, Somerville, MA, USA, 02145

Website

https://www.bluebirdbio.com

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Executives

Richard A Colvin	officer: Chief Medical Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Andrew Obenshain	officer: President of SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Christopher Krawtschuk	officer: Chief Financial Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Thomas J Klima	officer: Chief Commercial Officer, SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A. Paulson	director	85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Elisabeth Leiderman	director	1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole	officer: SVP, Secy. & General Counsel	C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann	officer: Chief Regulatory Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman	officer: Chief Financial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten	officer: Chief Accounting Officer	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145